Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Yidu Tech Inc.
醫渡科技有限公司
(incorporated in the Cayman Islands with limited liability)
(Stock Code: 2158)

VOLUNTARY ANNOUNCEMENT SUCCESSFUL BIDDING FOR PHASE III CLINICAL STUDY PROJECT OF RECOMBINANT HUMAN NEUROGENESIS FACTOR (SMR001) EYE DROP

Yidu Tech Inc. (the "**Company**" or "**Yidu Tech**") is pleased to announce that Tianjin Happy Life Technology Co., Ltd.* (天津開心生活科技有限公司), an associate of the Company, has recently won the bid for Shandong Yandu Biotechnology Co., Ltd.* (山東衍渡生物科技有限公司) for the Phase III Clinical Study Project of Recombinant Human Neurogenesis Factor (SMR001) Eye Drop, with a total project amount of approximately RMB55,817,597.00.

As a driving force in China's AI-powered healthcare transformation, Yidu Tech adheres to the mission of making precision healthcare accessible to everyone. We are dedicated to delivering professional, efficient, precise, and inclusive AI medical products and solutions. Powered by our proprietary core algorithm engine, YiduCore, we have built a "data-algorithm-scenario" flywheel ecosystem that enables efficient innovation and cost-effective, scalable applications of AI technologies across the entire healthcare value chain — spanning healthcare services, pharmaceuticals, insurance, and patients with the aim of promoting intelligent decision-making and empowerment.

The core value of AI medical lies in enhancing the quality and efficiency of medical evidence generation. By optimizing the full lifecycle of research, diagnosis, and treatment, we help make healthcare services safer, better, and more accessible. Yidu Tech continuously drives improvements in healthcare services efficiency and accessibility: empowering healthcare providers with precise and effective decision-making tools; accelerating the path from molecule to patient for pharmaceutical companies; delivering affordable, precise diagnosis and treatment to patients; and supporting public health systems with scientific insights. At the heart of all this is a profound respect for each individual life and a steadfast commitment to safeguarding the health and well-being of all.

By order of the Board
Yidu Tech Inc.
Gong Yingying
Executive Director and Chairlady

Hong Kong, 23 September, 2025

As at the date of this announcement, the executive Directors are Ms. Gong Yingying, Mr. Xu Jiming, Dr. Xie Li, and Ms. Feng Xiaoying; the non-executive Director is Mr. Zeng Ming; and the independent non-executive Directors are Dr. Ma Wei-Ying, Ms. Pan Rongrong and Prof. Zhang Linqi.